New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
08:58 EDTACT, IPXLImpax appoints G. Frederick Wilkinson as CEOActavis
Impax Laboratories (IPXL) has appointed G. Frederick Wilkinson as Impax's president and CEO effective April 29. Mr. Wilkinson, who previously served as President, Actavis Global Research and Development at Actavis (ACT), succeeds Larry Hsu, Ph.D. who is retiring.
News For IPXL;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 15, 2015
12:13 EDTACTThird Point gives quarterly update on stakes
NEW STAKES: Yum! Brands (YUM), NXP Semiconductors (NXPI), FedEx (FDX), McKesson (MCK), and J M Smucker (SJM). INCREASED STAKES: Actavis (ACT), Roper Technologies (ROP), Delta Air Lines (DAL), and FleetCor Technologies (FLT). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Phillips 66 (PSX), eBay (EBAY), and Anheuser Busch Inbev SA (BUD). LIQUIDATED STAKES: Alibaba Group (BABA), Citigroup (C), EMC Corporation (EMC), Anglo American (AAL), and Williams Companies (WMB).
09:29 EDTACTActavis: Warner Chilcott has held talks with DOJ over sales tactics, WSJ says
Subscribe for More Information
08:30 EDTACTActavis price target raised to $360 from $325 at Susquehanna
Subscribe for More Information
May 13, 2015
16:39 EDTACTAdamas Pharmaceuticals sees Namzaric launching in coming months
During its Q1 earnings report, Adamas (ADMS) stated, "In the coming months, we look forward to expanding our wholly-owned product pipeline with the initiation of a phase 2 clinical trial of ADS-5102 for a second CNS-related indication, completing enrollment in one of two ongoing phase 3 trials assessing ADS-5102 for the treatment of LID, and the U.S. launch of Namzaric by our collaborator, Actavis (ACT)."
May 11, 2015
19:15 EDTIPXLOn The Fly: After Hours Movers
Subscribe for More Information
16:43 EDTIPXLImpax performs GMP, pre-approval inspections of Impax Hayward facility
Subscribe for More Information
16:15 EDTIPXLImpax says FDA issued Form 483 after facility inspection
Subscribe for More Information
16:14 EDTIPXLImpax reaffirms outlook for 2015
Impax still sees 2015 adjusted gross margins as a percent of total revenue are expected to be in the mid 50% range, adjusted total research and development expenses across the generic and brand divisions of $80M-$85M and capital expenditures of $45M-$50M.
16:13 EDTIPXLImpax reports Q1 adjusted EPS 9c, consensus 18c
Reports Q1 revenue $143.1M, consensus $146.13M. The company said, "This quarter's revenues were negatively impacted by the later than anticipated close of the Tower acquisition, the delayed launch of lamotrigine ODT, which was launched in April due to delayed receipt of inventory from our supplier, and the deferred recognition of product sales from the launch of RYTARY. In addition, product sales mix in the combined portfolio as well as costs related to successfully launching RYTARY and the financing of the Tower acquisition led to a reduction in our first quarter earnings."
15:00 EDTIPXLNotable companies reporting after market close
Subscribe for More Information
12:51 EDTACTOn The Fly: Top stock stories at midday
Subscribe for More Information
09:21 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTACTActavis says committed to utilizing FCF to accelerate debt repayment
Subscribe for More Information
08:57 EDTACTActavis says 'doing exceptionally well' on cost synergy capture
Subscribe for More Information
08:52 EDTACTActavis sets 'aspirational' FY17 EPS target of $25
Subscribe for More Information
08:48 EDTACTActavis sees sNDA submission for low dosage Linzess in 2016
Subscribe for More Information
06:40 EDTACTActavis sees Eluxadoline, Cariprazine PDUFAs in Q2
Subscribe for More Information
06:37 EDTACTActavis sees 2015 EPS $17.00-$18.50, consensus $17.70
Sees 2015 pro forma revenue $22M-$22.5B, consensus $21.47B. Sees 2015 total net revenue $20.5B-$21B.
06:35 EDTACTActavis reports Q1 EPS $4.30, consensus $3.94
Reports Q1 revenue $4.23B., consensus $4.03B. Reports adjusted EBITDA of $1.78B compared to $860M last year. Results include the contribution from Allergan businesses for the period following the close on March 17.
May 10, 2015
19:25 EDTACTCourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use